Patents Assigned to CRAGE Medical Co., Limited
-
Publication number: 20240131065Abstract: An engineered immune cell for immunotherapy, which has a relatively high persistence and/or survival rate of transplantation in a host organism, and a preparation method therefor.Type: ApplicationFiled: February 25, 2022Publication date: April 25, 2024Applicant: CRAGE MEDICAL CO., LIMITEDInventors: Zonghai LI, Zhimin SHI
-
Publication number: 20230310600Abstract: Provided are a method for engineering T-cells or pluripotent stem cells, as well as engineered T-cells and pluripotent stem cells. The method specifically comprises: engineering the T cells or pluripotent stem cells to obtain engineered T cell or engineered pluripotent stem cells with reduced expression, activity, and/or signaling of NKG2A. The obtained engineered T cell and a composition containing the engineered T cell can be used to treat diseases, such as cancer (tumor) and autoimmune diseases.Type: ApplicationFiled: August 9, 2021Publication date: October 5, 2023Applicant: CRAGE MEDICAL CO., LIMITEDInventors: Zonghai LI, Zhaohui LIAO
-
Publication number: 20230272341Abstract: Provided is an immune effector cell targeting FAP and another tumor-associated antigen, which can improve a tumor microenvironment, kill tumor cells, and can be used to treat tumors.Type: ApplicationFiled: August 10, 2021Publication date: August 31, 2023Applicant: CRAGE MEDICAL CO., LIMITEDInventors: Zonghai LI, Ruixin SUN
-
Publication number: 20230158071Abstract: Provided is a method for tumor treatment, comprising administering immune effector cells and a PARP inhibitor to an individual suffering from a tumor, the immune effector cell expresses a receptor for identifying a tumor antigen. Further provided is a kit for tumor treatment.Type: ApplicationFiled: December 9, 2019Publication date: May 25, 2023Applicant: CRAGE medical Co., LimitedInventors: Zonghai LI, Ruixin SUN
-
Publication number: 20230148586Abstract: The present application relates to the field of cell biology. The present application provides a cryopreservation medium for cryogenic storage of a biological sample, particularly a cryopreservation medium for cryogenic storage of cells in an apheresis sample.Type: ApplicationFiled: April 21, 2021Publication date: May 18, 2023Applicant: CRAGE MEDICAL CO., LIMITEDInventors: Zonghai LI, Huamao WANG, Huiping GAO
-
Publication number: 20230143947Abstract: Provided is a genetically engineered immune effector cell, wherein the immune effector cell expresses a receptor specifically recognizing a target antigen and IL7, and the IL-7 is inducibly expressed and regulated by the receptor. Further provided are a nucleic acid molecule expressing the receptor and IL7 in the immune effector cell and a method for preparing the immune effector cell.Type: ApplicationFiled: September 21, 2020Publication date: May 11, 2023Applicant: CRAGE MEDICAL CO., LIMITEDInventors: Zonghai LI, Hua JIANG
-
Patent number: 11596653Abstract: Disclosed herein are methods of treating a subject exhibiting a solid tumor that expresses Glypican-3 (GPC3). The methods typically utilize g GPC3 chimeric antigen receptor immunoresponsive cells to a subject in need thereof to effect killing of tumor cells.Type: GrantFiled: October 19, 2018Date of Patent: March 7, 2023Assignee: CRAGE MEDICAL CO., LIMITEDInventors: Zonghai Li, Huiping Gao, Peng Wang, Hua Jiang, Huamao Wang
-
Publication number: 20230061005Abstract: Provided is an antibody or antigen binding fragment, capable of recognizing an antigen peptide comprising SEQ ID NO: 7 (KNKKIYDGG); or recognizing an epitope comprising SEQ ID NO: 7 in Claudin 18.2; preferably recognizing a peptide comprising SEQ ID NO: 6 (KNKKIYDGGART); or recognizing an epitope comprising the SEQ ID NO: 6 in the Claudin 18.2.Type: ApplicationFiled: January 4, 2021Publication date: March 2, 2023Applicant: CRAGE MEDICAL CO., LIMITEDInventors: Zonghai LI, Peng WANG, Zhen LIU, Huamao WANG
-
Patent number: 11530270Abstract: Provided is an antibody that specifically recognizes IL-13RA2, which can be used in the manufacture of a targeting anti-tumor medicament as well as a medicament for diagnosing a tumor.Type: GrantFiled: February 8, 2018Date of Patent: December 20, 2022Assignee: CRAGE medical Co., LimitedInventors: Peng Wang, Huamao Wang
-
Patent number: 11525006Abstract: Provided in the present invention are a specific antibody of BCMA and a BCMA-targeting immune effector cell, and also provided are a chimeric antigen receptor-modified T cell prepared using the antibody and the use thereof.Type: GrantFiled: January 23, 2018Date of Patent: December 13, 2022Assignee: CRAGE medical Co., LimitedInventors: Peng Wang, Huamao Wang, Hua Jiang
-
Publication number: 20220356447Abstract: The present invention relates to a cell resistant to transplantation immune rejection. The cell expresses a first protein recognizing one or more immune effector cells of a host; preferably the cell has the function of inhibiting or killing the immune effector cells of the host. The present invention also relates to a method for preventing or regulating transplantation immune rejection, and a method for preventing or regulating the attack of NK cells on exogenous cells.Type: ApplicationFiled: June 29, 2020Publication date: November 10, 2022Applicant: CRAGE medical Co., LimitedInventors: Zonghai LI, Zhaohui LIAO
-
Publication number: 20220325241Abstract: Provided are an immune effector cell for co-expressing a chemokine receptor, a pharmaceutical composition, a kit, and a method for treating a tumor. The immune effector cell comprises a receptor that specifically recognizes claudin 18.2 and a protein that recognizes SDF-1. Further provided are an expression construct, an expression vector, and a virus. The expression construct comprises an expression of a receptor that binds to a tumor-associated antigen and an expression of the protein that recognizes SDF-1, which are connected in sequence.Type: ApplicationFiled: August 10, 2020Publication date: October 13, 2022Applicant: CRAGE MEDICAL CO., LIMITEDInventors: Zonghai LI, Ruixin SUN
-
Patent number: 11453860Abstract: Provided are a GPC3 and ASGPR1 double-targeted transgenic immune effector cell and use thereof. The cell is an immune effector cell capable of identifying the gene modification of GPC3 and ASGPR1 simultaneously, and the cell can be used in the treatment of GPC3 and ASGPR1 double positive tumours, such as liver cancer.Type: GrantFiled: November 30, 2015Date of Patent: September 27, 2022Assignee: CRAGE MEDICAL CO., LIMITEDInventors: Huamao Wang, Xiumei Cai, Hongxia Zhao, Bo Song, Yuanmei Chen, Yinyu Zhu
-
Patent number: 11447570Abstract: A binding unit that specifically binds to fibroblast activation protein ? (FAP?), a polynucleotide that encodes the binding unit, a vector that comprises the polynucleotide and a host cell, a method for use in producing the antigen-binding unit and a method for treating a disease by using the FAP?-specific binding unit; the binding unit that specifically binds to FAP? may efficiently bind to tumor cells that express FAP?, and immune effector cells comprising the binding unit exhibit significant killing capabilities against tumor cells that express FAP.Type: GrantFiled: November 16, 2018Date of Patent: September 20, 2022Assignee: CRAGE MEDICAL CO., LIMITEDInventors: Zonghai Li, Peng Wang
-
Patent number: 11427633Abstract: Disclosed are an anti-CD19 humanized antibody prepared from a murine monoclonal antibody, a chimeric antigen receptor containing the humanized antibody, and an immune cell expressing the humanized antibody. Not only does the humanized antibody of the present invention not produce an anti-antibody response (AAR) and a human anti-mouse antibody response (HAMA), but same also has better affinity than a murine antibody, and has excellent activity and safety, thereby providing a new means for treating CD19-expressing tumors.Type: GrantFiled: December 13, 2017Date of Patent: August 30, 2022Assignee: CRAGE medical Co., LimitedInventors: Peng Wang, Huiping Gao, Zhimin Shi, Zonghai Li
-
Patent number: 11419895Abstract: Disclosed herein are methods of treating a subject exhibiting a cell that expresses Wilms tumor protein 1 (WT1). The methods typically utilize anti-WT1 antigen binding units or chimeric antigen receptor immunoresponsive cells to a subject in need thereof to effect killing of tumor cells.Type: GrantFiled: May 30, 2018Date of Patent: August 23, 2022Assignee: CRAGE medical Co., LimitedInventors: Zonghai Li, Peng Wang, Hua Jiang
-
Patent number: 11299525Abstract: Provided is a chimeric antigen receptor-modified immune effector cell carrying a procedural death ligand 1 (PD-L1) blocking agent. Also provided is a method for secreting and expressing a PD-L1 blocking agent using the immune effector cell as a carrier to improve the anti-tumour effect of the chimeric antigen receptor-modified immune effector cell.Type: GrantFiled: October 31, 2016Date of Patent: April 12, 2022Assignee: CRAGE Medical Co., LimitedInventors: Zonghai Li, Zeyan Pan, Zhimin Shi, Bo Song, Peng Wang